Clinical Trials on Fallopian Tube Cancer Stage IV

Total 5027 results

Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Stage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditions

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian... and other conditions

United States
National Cancer Institute (NCI)

Completed

Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Stage IV Fallopian Tube Cancer AJCC v6 and v7 | Stage IV Ovarian Cancer AJCC v6 and v7 | Stage IV Primary Peritoneal Cancer AJCC v7

United States
University of Washington
National Cancer Institute (NCI)

Terminated

IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery

Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian Cancer | Stage IIIB Primary Peritoneal Cancer | Stage IIIC Fallopian Tube Cancer | Stage IIIC Ovarian Cancer | Stage IIIC Primary Peritoneal Cancer and other conditions

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Withdrawn

PET Imaging of Ovarian Carcinoma With 18F-FSPG

Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian Cancer | Stage IIIB Primary Peritoneal Cancer | Stage IIIC Fallopian Tube Cancer | Stage IIIC Ovarian Cancer | Stage IIIC Primary Peritoneal Cancer and other conditions
Gynecologic Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Stage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage II Ovarian Cancer AJCC v6 and v7 | Stage IIA Fallopian Tube Cancer AJCC v6 and v7 | Stage IIB Fallopian... and other conditions

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Sanofi Pasteur, a Sanofi Company

Completed

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIA Fallopian Tube Cancer | Stage IIB Fallopian Tube Cancer | Stage IIC Fallopian Tube Cancer | Stage... and other conditions

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission

Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIA Fallopian Tube Cancer | Stage IIB Fallopian Tube Cancer | Stage IIC Fallopian Tube Cancer | Stage... and other conditions
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIC Fallopian Tube Cancer and other conditions

Canada
Memorial Sloan Kettering Cancer Center

Recruiting

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage III Ovarian Cancer | Stage III Fallopian Tube Cancer | Stage II Ovary Cancer | Stage II Ovarian Cancer | Stage III Ovary Cancer and other conditions

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Malignant Ovarian Clear Cell Tumor | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian... and other conditions
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage IIA Fallopian Tube Cancer | Stage... and other conditions

United States
Precigen, Inc

Recruiting

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Stage III Fallopian Tube... and other conditions

United States
Jerome Canady, M.D.

Active, not recruiting

Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites

Stage IV Lung Cancer | Stage IV Bladder Cancer | Stage IV Pancreatic Cancer | Recurrent Malignant Solid Neoplasm | Stage IV Breast Cancer | Stage IV Renal Cell Cancer | Stage IV Prostate Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Stage IV Gastric Cancer | Stage IV Non-small Cell Lung Cancer | Stage... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Fatigue | Anxiety | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC... and other conditions

United States
Fondazione Policlinico Universitario Agostino Gemelli...
Istituto Di Ricerche Farmacologiche Mario Negri; Foundation Medicine

Recruiting

Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination (MITO25)

Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Italy
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IIIA Fallopian Tube Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA Primary Peritoneal Cancer AJCC v8 | Stage IIIA1 Fallopian Tube Cancer AJCC v8 | Stage... and other conditions

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

Pain | Neuropathy | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian Cancer | Stage IIIB Primary Peritoneal Cancer | Stage IIIC Fallopian Tube Cancer | Stage IIIC Ovarian Cancer | Stage IIIC Primary... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Sprint for Life

Completed

Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Primary Peritoneal High Grade Serous Adenocarcinoma | Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IIIA Fallopian Tube Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous... and other conditions

United States, Korea, Republic of, Canada, Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (POSITION)

Fallopian Tube Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage IIIA Fallopian Tube Cancer AJCC v7 | Stage IIIA Ovarian Cancer AJCC v6 and v7 | Stage IIIA Primary Peritoneal Cancer AJCC v7 and other conditions

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Primary Peritoneal Endometrioid... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy

Fallopian Tube Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Malignant Ovarian Brenner Tumor and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Nausea and Vomiting | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma | Stage IIA Fallopian Tube Cancer | Stage... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary Peritoneal Cancer AJCC v8

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Primary Cytoreductive Surgery

Ovarian Cancer | Fallopian Tube Cancer | Fallopian Tube Carcinoma | Peritoneal Carcinoma | Ovarian Carcinoma | Peritoneal Cancer | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Fallopian Tube Cancer Stage IIIC | Fallopian Tube Cancer Stage IV

United States
Centre Oscar Lambret
Institut National de la Santé Et de la Recherche Médicale, France

Recruiting

Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer (TILsOV-1805)

Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Fallopian Tube Cancer Stage IIIC | Fallopian Tube Cancer Stage IV

France
National Cancer Institute (NCI)

Completed

RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage IV Primary Peritoneal Cancer

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IA Ovarian Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Ovarian Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage IIIA Fallopian Tube Cancer AJCC v7 | Stage IIIA Ovarian Cancer AJCC v6 and v7 | Stage IIIA Primary Peritoneal Cancer AJCC v7 | Stage IIIB Fallopian Tube Cancer... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage IIIA Fallopian Tube Cancer AJCC v7 | Stage IIIA Ovarian Cancer AJCC v6 and v7 | Stage IIIA Primary Peritoneal Cancer AJCC v7 | Stage IIIB Fallopian Tube Cancer... and other conditions

United States
M.D. Anderson Cancer Center

Active, not recruiting

Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage IIIA Fallopian Tube Cancer AJCC v7 | Stage IIIA Ovarian Cancer AJCC v6 and v7 | Stage IIIA Primary Peritoneal Cancer AJCC v7 | Stage IIIB Fallopian Tube Cancer... and other conditions

United States
Women's Hospital School Of Medicine Zhejiang University
Sun Yat-sen University; Qilu Hospital of Shandong University; Second Affiliated... and other collaborators

Recruiting

Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer

Epithelial Ovarian Carcinoma Stage III | Epithelial Ovarian Carcinoma Stage IV | Fallopian Tube Carcinoma Stage III | Fallopian Tube Carcinoma Stage IV | Primary Peritoneal Carcinoma Stage III | Primary Peritoneal Carcinoma Stage IV

China
GOG Foundation
GlaxoSmithKline

Recruiting

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer (HOTT)

Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage IV Primary Peritoneal Cancer | Stage III Ovarian Cancer | Stage III Primary Peritoneal Cancer | Stage III Fallopian Tube Cancer

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Withdrawn

ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Primary Peritoneal High Grade Serous Adenocarcinoma | Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage IIIA Fallopian Tube Cancer AJCC v7 | Stage IIIA Ovarian Cancer AJCC v6 and v7 | Stage IIIA Primary Peritoneal... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma and other conditions

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary Peritoneal Cancer AJCC v8 | Stage II Fallopian Tube Cancer AJCC v8 | Stage II Ovarian... and other conditions

United States, Canada, Korea, Republic of, Puerto Rico, Ireland
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Recruiting

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Ovarian Cancer Stage IV | Ovarian Cancer Stage III | Fallopian Tube Cancer Stage IV | Fallopian Tube Cancer Stage III

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Stage III Fallopian Tube Cancer AJCC v7 | Stage III Primary Peritoneal Cancer... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Stage IIIC Fallopian Tube Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IIIC Primary Peritoneal Cancer AJCC v8 | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary Peritoneal Cancer AJCC v8 | Advanced Ovarian Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Carcinoma | Ovarian Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell... and other conditions

United States
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma and other conditions

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Active, not recruiting

Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Stage IIIC Fallopian Tube Cancer | Stage IIIC Ovarian Cancer | Stage IIIC Primary Peritoneal Cancer | Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage IV Primary Peritoneal Cancer

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Metastatic Melanoma | Advanced Malignant Solid Neoplasm | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage... and other conditions

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Withdrawn

Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer

Stage II Uterine Corpus Cancer AJCC v7 | Uterine Carcinosarcoma | Endometrial Carcinoma | Stage II Cervical Cancer AJCC v7 | Stage IIA Cervical Cancer AJCC v7 | Stage IIB Cervical Cancer AJCC v6 and v7 | Stage IIIB Cervical Cancer AJCC v6 and v7 | Stage IVA Cervical Cancer AJCC v6 and v7 | Stage 0 Fallopian... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Primary Peritoneal Clear... and other conditions

United States
Pamela Munster
Pfizer; Xynomic Pharmaceuticals, Inc.

Withdrawn

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

Clinical Trials on Fallopian Tube Cancer Stage IV

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations